News about Drug Discovery & Development

Partner Therapeutics Submits sBLA to FDA for BIZENGRI

Partner Therapeutics submits sBLA to FDA for BIZENGRI in NRG1 fusion-positive cholangiocarcinoma, supported by eNRGy study data showing 36.8 percent response rate and durable efficacy.

Drug Discovery & Development | 15/04/2026 | By News Bureau

Haisco Signs Exclusive Deal with AbbVie to Develop Novel Pain Therapies

Haisco partners with AbbVie to develop novel pain therapies, with multiple compounds in preclinical to Phase 1 stages targeting pain-related conditions.

Drug Discovery & Development | 13/04/2026 | By News Bureau

Artivion Secures US FDA Approval for Endospan's NEXUS Aortic Arch System

Artivion, Inc., a leading cardiac and vascular surgery company focused on aortic disease, announced that the US Food and Drug Administration (FDA) has approved the premarket approval application (PMA) for the NEXUS Aortic Arch System, developed by Endospan Ltd. (Endospan), Artivion's long-standing partner.

Drug Discovery & Development | 08/04/2026 | By Darshana

Concept Medical Unveils Landmark SirPAD Trial at ACC 2026, Advancing PAD Treatment

Concept Medical Inc. (CMI), a global leader in drug-delivery technologies for vascular interventions, has announced the presentation of the world’s largest randomized controlled trial evaluating a sirolimus-coated balloon (SCB) for peripheral artery disease (PAD) at the ACC 2026 Scientific Sessions.

Drug Discovery & Development | 01/04/2026 | By Darshana |  106

Wockhardt's Zaynich Gets CDSCO SEC Nod for Gram-Negative Infections

CDSCO’s Subject Expert Committee (SEC) recommends Wockhardt’s Zaynich (Zidebactam/Cefepime) for Gram-negative infections, paving the way for DCGI approval of the novel antibiotic in India.

Drug Discovery & Development | 30/03/2026 | By News Bureau |  108

Takeda's Zasocitinib Shows Strong Skin Clearance in Psoriasis Study

Takeda reports Phase 3 data showing zasocitinib delivers rapid, durable skin clearance in psoriasis, with ~70 percent achieving sPGA 0/1 and early PASI 75 response, with a consistent safety profile.

Drug Discovery & Development | 30/03/2026 | By News Bureau

PharmaJet, REDE-TB to Launch Clinical Study on Needle-Free TB Skin Testing Technology

The study will evaluate accuracy, safety and patient acceptance of needle-free Tropis system compared to traditional tuberculin skin test

Drug Discovery & Development | 26/03/2026 | By News Bureau

LB Pharmaceuticals Starts Phase 3 Trial for LB-102 in Schizophrenia

LB Pharmaceuticals initiates Phase 3 NOVA-2 trial of LB-102 for schizophrenia, enrolling ~460 patients to assess PANSS score, symptoms and safety, with topline results expected in 2H 2027.

Drug Discovery & Development | 26/03/2026 | By News Bureau |  109

Dupixent Approval in Japan Boosts Biologics Manufacturing Demand for Sanofi and Regeneron

The Ministry of Health, Labour and Welfare has granted marketing and manufacturing authorization to Dupixent (dupilumab) for the treatment of adults with moderate-to-severe bullous pemphigoid (BP), a rare and debilitating skin disorder.

Drug Discovery & Development | 25/03/2026 | By Darshana |  103

Biotheryx Doses First Patient in Dose Expansion Trial of BTX-9341 for Advanced Breast Cancer

Biotheryx advances BTX-9341 into a dose expansion trial with fulvestrant for HR+/HER2- breast cancer, aiming to overcome resistance in patients previously treated with CDK4/6 inhibitors.

Drug Discovery & Development | 19/03/2026 | By News Bureau